A preliminary pharmacogenetic investigation of adverse events from topiramate in heavy drinkers

Center for Alcohol and Addiction Studies, Brown University, Providence, RI, USA.
Experimental and Clinical Psychopharmacology (Impact Factor: 2.63). 05/2009; 17(2):122-9. DOI: 10.1037/a0015700
Source: PubMed

ABSTRACT Topiramate, an anticonvulsant medication, is an efficacious treatment for alcohol dependence. To date, little is known about genetic moderators of side effects from topiramate. The objective of this study was to examine 3 single nucleotide polymorphisms (SNPs) of the glutamate receptor GluR5 gene (GRIK1) as predictors of topiramate-induced side effects in the context of a laboratory study of topiramate. Heavy drinkers (n=51, 19 women and 32 men), 75% of whom met criteria for an alcohol use disorder, completed a 5-week dose escalation schedule to a target dose of either 200 or 300 mg or matched placebo. The combined medication groups were compared with placebo-treated individuals for side effects at target dose. Analyses revealed that an SNP in intron 9 of the GRIK1 gene (rs2832407) was associated with the severity of topiramate-induced side effects and with serum levels of topiramate. Genes underlying glutamatergic neurotransmission, such as the GRIK1 gene, may help predict heterogeneity in topiramate-induced side effects. Future studies in larger samples are needed to more fully establish these preliminary findings.

Download full-text


Available from: Robert Swift, Aug 05, 2015
  • Source
    • "In the subsample of European Americans (n = 122), topiramate was effective in reducing heavy drinking days only in rs2832407 C-allele homozygotes . In addition, a previous pharmacogenetic analysis of the human laboratory pilot study mentioned previously (Miranda et al., 2008) showed that rs2832407 was associated with the severity of topiramate-induced side effects (Ray et al., 2009). The RCT by Kranzler et al. (2014) did not find an effect of the SNP on adverse events, suggesting that the kainate receptor does not play a unique role in mediating topiramate-related adverse effects. "
    The International Journal of Neuropsychopharmacology 06/2014; 17(10):1-4. DOI:10.1017/S1461145714000790 · 5.26 Impact Factor
  • Source
    • "Such findings on safety and mechanisms are vital to deciding whether to invest resources for efficacy testing for a putative addiction medication . Our team has used human laboratory paradigms to test several medications for addiction, including naltrexone (Ray, Bujarski, Chin, & Miotto, 2012; Ray & Hutchison, 2007), topiramate (Miranda et al., 2008; Ray et al., 2009), quetiapine (Moallem & Ray, 2012; Ray, Chin, Heydari, & Miotto, 2011), and varenicline (Ray et al., 2014, 2013). Given the new opportunities presented by recent discoveries on the role of neuroinflammation in addiction as well as new advancements in the technology of medication development , including the refinement of powerful human laboratory models, the stage is set for the discovery of novel treatments for substance use disorders. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Studies have implicated neuroinflammatory processes in the pathophysiology of various psychiatric conditions, including addictive disorders. Neuroimmune signaling represents an important and relatively poorly understood biological process in drug addiction. The objective of this review is to update the field on recent developments in neuroimmune therapies for addiction. First, we review studies of neuroinflammation in relation to alcohol and methamphetamine dependence followed by a section on neuroinflammation and accompanying neurocognitive dysfunction in HIV infection and concomitant substance abuse. Second, we provide a review of pharmacotherapies with neuroimmune properties and their potential development for the treatment of addictions. Pharmacotherapies covered in this review include ibudilast, minocycline, doxycycline, topiramate, indomethacin, rolipram, anakinra (IL-1Ra), peroxisome proliferator-activated receptor agonists, naltrexone, and naloxone. Lastly, summary and future directions are provided with recommendations for how to efficiently translate preclinical findings into clinical studies that can ultimately lead to novel and more effective pharmacotherapies for addiction.
    International Review of Neurobiology 01/2014; 118C:381-401. DOI:10.1016/B978-0-12-801284-0.00012-9 · 2.46 Impact Factor
  • Source
    • "Finally, pharmacogenomics is important not only in determining efficacy but also in identifying those who might suffer from adverse side effects. In a recent study, a single nucleotide polymorphism variant in the intron 9 of the glutamate receptor GluR5 gene (GRIK1) was associated with a higher severity of topiramate-induced side effects (Ray et al. 2009). "
    [Show abstract] [Hide abstract]
    ABSTRACT: More than 76 million people world-wide are estimated to have diagnosable alcohol use disorders (AUDs) (alcohol abuse or dependence), making these disorders a major global health problem. Pharmacotherapy offers promising means for treating AUDs, and significant progress has been made in the past 20 years. The US Food and Drug Administration approved three of the four medications for alcoholism in the last two decades. Unfortunately, these medications do not work for everyone, prompting the need for a personalized approach to optimize clinical benefit or more efficacious medications that can treat a wider range of patients, or both. To promote global health, the potential reorganization of the National Institutes of Health (NIH) must continue to support the National Institute on Alcohol Abuse and Alcoholism's (NIAAA's) vision of ensuring the development and delivery of new and more efficacious medications to treat AUDs in the coming decade. To achieve this objective, the NIAAA Medications Development Team has identified three fundamental long-range goals: (1) to make the drug development process more efficient; (2) to identify more efficacious medications, personalize treatment approaches, or both; and (3) to facilitate the implementation and adaptation of medications in real-world treatment settings. These goals will be carried out through seven key objectives. This paper describes those objectives in terms of rationale and strategy. Successful implementation of these objectives will result in the development of more efficacious and safe medications, provide a greater selection of therapy options and ultimately lessen the impact of this devastating disorder.
    Addiction Biology 03/2012; 17(3):513-27. DOI:10.1111/j.1369-1600.2012.00454.x · 5.93 Impact Factor
Show more